Molecular structure of CI 988, CAS Number: 130332-27-3
CI 988 (CAS 130332-27-3)
See product citations (1)
Application:
CI 988 is a selective and effective antagonist of CCK-BR
CAS Number:
130332-27-3
Purity:
>99%
Molecular Weight:
614.73
Molecular Formula:
C35H42N4O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CI 988 is a selective and effective antagonist of CCK-BR (CCK2 CCK-B cholecystokinin 2) receptors. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Lung cancer cell studies report that Cl 988 inhibits the proliferation of NCI-H209 cells in vitro and the binding of CCK-8 to NCI-H209 cells. In addition Cl 988 blocks the elevated levels of cytosolic Ca2+ induced by CCK-8. Other CCK-BR inhibitors include L-365,260 (sc-205244).
CI 988 (CAS 130332-27-3) References
- Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988. | Dethloff, LA., et al. 1999. Food Chem Toxicol. 37: 105-10. PMID: 10227733
- Cholecystokinin/opioid interactions. | Wiesenfeld-Hallin, Z., et al. 1999. Brain Res. 848: 78-89. PMID: 10612699
- Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats. | Coudoré-Civiale, MA., et al. 2000. Pain. 88: 15-22. PMID: 11098095
- CI-988 inhibits growth of small cell lung cancer cells. | Moody, TW. and Jensen, RT. 2001. J Pharmacol Exp Ther. 299: 1154-60. PMID: 11714907
- The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. | Singh, L., et al. 1991. Br J Pharmacol. 104: 239-45. PMID: 1686205
- Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. | Carrillo, J., et al. 2009. Anticancer Drugs. 20: 527-33. PMID: 19407653
- Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. | Hughes, J., et al. 1990. Proc Natl Acad Sci U S A. 87: 6728-32. PMID: 1975695
- Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats. | Kim, J., et al. 2015. Korean J Physiol Pharmacol. 19: 125-30. PMID: 25729274
- CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. | Moody, TW., et al. 2015. J Mol Neurosci. 56: 663-72. PMID: 25761747
- Gastrin Attenuates Renal Ischemia/Reperfusion Injury by a PI3K/Akt/Bad-Mediated Anti-apoptosis Signaling. | Liu, C., et al. 2020. Front Pharmacol. 11: 540479. PMID: 33343341
- The CCK-B antagonist CI-988 increases dopamine levels in microdialysate from the rat nucleus accumbens via a tetrodotoxin- and calcium-independent mechanism. | Corwin, RL., et al. 1995. J Neurochem. 65: 208-17. PMID: 7790862
- Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. | Bradwejn, J., et al. 1995. Biol Psychiatry. 38: 742-6. PMID: 8580227
- A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. | Adams, JB., et al. 1995. J Clin Psychopharmacol. 15: 428-34. PMID: 8748432
Inhibitor of:
CCK-BR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CI 988, 10 mg | sc-205244 | 10 mg | $800.00 | |||
| US: Only available in the US | ||||||
CI 988, 50 mg | sc-205244A | 50 mg | $1503.00 | |||
| US: Only available in the US | ||||||